The U.S. Food and Drug Administration (FDA) has committed to unprecedented transparency by pledging to publish complete response letters (CRLs) to drug developers at the time they are issued. This initiative builds on July 2025’s first mass release of over 200 CRLs and aims to enhance public trust in regulatory decisions. The agency concurrently released 89 previously undisclosed CRLs covering applications from 2024 onward, shedding new light on FDA's evaluation process, including detailed rationales behind high-profile drug rejections. This real-time release aligns with FDA Commissioner Marty Makary’s vision for radical transparency in drug approval processes.